Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Merck & Co., Inc.
MRK
$114.24 (+ $1.68 + 1.49%)
Last updated: Previous Close (2026-05-19)
About the Company
Merck & Co., Inc. operates as a leading healthcare company worldwide, focusing on human health pharmaceuticals, vaccines, and animal health products. Its portfolio includes blockbuster drugs like Keytruda for immuno-oncology, Gardasil for human papillomavirus prevention, and a range of treatments such as Welireg, ProQuad, Winrevair, Januvia, and others addressing cancer, infectious diseases, cardiometabolic conditions, and more. The company also provides veterinary solutions including Nuflor and Bovilis for livestock health management. With a substantial presence in oncology, its Keytruda leads sales contributions, complemented by vaccines targeting pediatric diseases. Merck & Co., Inc. generates significant revenue—$64.17 billion in 2024—from pharmaceuticals and vaccines, primarily in the U.S., while maintaining a diversified global footprint across consumer, business, and government sectors. Employing around 75,000 people, it plays a pivotal role in advancing treatments for chronic and infectious diseases, driving innovation in biopharmaceuticals and immunotherapy.
Price History
Latest News for MRK
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
Investing.com -- Pharmaceutical giant Merck announced Wednesday that it will acquire clinical-stage oncology company Terns Pharmaceuticals for $53.00 per share in cash, representing an approximate equity value of $6.7 billion. The deal equates to approximately $5.7 billion net of acquired cash and represents a premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock price on Tuesday.
Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating. On March 18, 2026, Merck’s Animal Health division announced that the FDA approved […]
MSD and Quotient collaborate on IBD drug targets
The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have ent
Update: Market Chatter: Merck Nears $6 Billion Deal to Acquire Terns Pharma
(Updates with Terns ticker symbol in the first paragraph and latest stock move in the fifth paragrap
Assessing Merck (MRK) Valuation After New IBD Genetics Collaboration With Quotient Therapeutics
Why Merck’s new IBD genetics deal matters for MRK stock Merck (MRK) just signed a multi year research collaboration with Quotient Therapeutics focused on inflammatory bowel disease, built around Quotient’s somatic genomics platform and a milestone structure worth up to US$2.2b. Quotient receives an upfront US$20 million payment, while Merck gains access to a technology that examines naturally occurring somatic mutations in patient tissues to identify targets that may drive or protect against...